SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stem Cell Research
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (478)11/17/2010 4:28:28 AM
From: nigel bates   of 495
 
They have a third program which might enter the clinic in 2012. This is of more than passing interest to me, as I have early signs of retinitis pigmentosa.
Of the three programs, I would guess it is the one with the best chance of eventual success.

"....Our ReN003 programme for diseases of the retina also made marked progress during the period. In February 2010, our ongoing US collaboration with the Schepens Eye Research Institute at Harvard Medical School was the recipient of an industrial grant from a major US specialty healthcare company. This funding represents a strong endorsement of the potential of the programme and has been directed towards the first phase of a two year translational programme to take human retinal progenitor cells (hRPCs) towards the clinic in the US, initially as a candidate cell-based therapy for retinitis pigmentosa, a blindness-causing disease of the retina. However, the hRPCs developed in the programme will almost certainly be applicable as cell therapy candidates for other blindness-causing diseases, such as age-related macular degeneration and diabetic retinopathy.

One of the key objectives of this first funded phase of the ReN003 programme has already been achieved, notably yield optimisation of the hRPCs in culture, at quantities sufficient for future clinical studies. Subject to regulatory advice and the results of further pre-clinical studies, we anticipate that this programme will also enter its clinical phase in 2012..."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News